EV
Evangelos
Community Contributor
Followers25Total number of followers
Comments0Total number of comments
Member Since2023Date joined
EV
Community Contributor
Bristol Myers Squibb (BMY): Undervalued Opportunity or Value Trap? A Deep Dive into 2024 Earnings and Fair Value
Fourth Quarter 2024 Highlights: Total Revenues: $12.3 billion, an 8% increase from the same period in 2023. GAAP Earnings Per Share (EPS): $0.04, a significant decrease from $0.87 in Q4 2023.
View narrativeUS$65.00
FV
7.0% undervalued intrinsic discount2.43%
Revenue growth p.a.
2users have liked this narrative
0users have commented on this narrative
9users have followed this narrative
25 days ago author updated this narrative
EV
Community Contributor
Medtronic Stock: A Compelling Buy for Value and Income Investors as Robotics, Innovation Catalysts Ignite Upside to $105+
Strengths and Competitive Advantages: Diverse Product Portfolio: Medtronic operates across four key segments—Cardiovascular, Medical-Surgical, Neuroscience, and Diabetes—providing revenue stability and reducing dependency on any single product line. This diversification surpasses more specialized competitors like Boston Scientific (focused on cardiovascular) or Intuitive Surgical (robotics).
View narrativeUS$95.00
FV
4.0% undervalued intrinsic discount5.15%
Revenue growth p.a.
10users have liked this narrative
0users have commented on this narrative
19users have followed this narrative
about 1 month ago author updated this narrative